VERASTEM INC
PharmaVERASTEM INC is a pharmaceutical company focused on Oncology. Key products include AVMAPKI FAKZYNJA CO-PACK (COPACKAGED).
FDA Novel Drug Designations
(2025)See 1 novel approval →
VERASTEM INC at a Glance
- Fast trial execution (28 months median completion)
VERASTEM INC's Key Drugs
VERASTEM INC's core commercial portfolio centers on AVMAPKI FAKZYNJA CO-PACK (COPACKAGED), spanning Oncology — its most strategically important drugs approved in the last 15 years.
VERASTEM INC's Recent FDA Approvals
VERASTEM INC secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
VERASTEM INC's Therapeutic Areas
VERASTEM INC's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
VERASTEM INC's Top Competitors
VERASTEM INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
VERASTEM INC Pipeline Snapshot
VERASTEM INC has 17 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 5 Phase 2 and 11 Phase 1.
Phase 3 Readout Calendar Pro
1 Phase 3 trial with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) leads revenue
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/1 completed
- • Speed: 28 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2025-05-08
- Latest
- 2025-05-08
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges